You are here

News

Genomics Leading Innovation in BC

Monday, December 16, 2013

Seven new innovative research projects have been funded through Genome BC’s Strategic Opportunities Fund (SOF). The SOF program, with funding provided by Genome BC and several partners, aims to catalyze new projects and initiatives of strategic importance to BC’s economic sectors. These investments are increasingly recognized for providing foundational research and the projects provide an important basis for future research.

UCB Canada supports efforts to identify personalized treatment approach for drug-resistant epilepsy

Monday, December 9, 2013

Genome Canada and Génome Québec are pleased to announce UCB Canada Inc.’s contribution to a four-year study aimed at developing a personalized medicine approach to the early diagnosis of various types of epilepsy. The $10.8 million project, “Personalized medicine in the treatment of epilepsy”, forms the Canadian Epilepsy Network (CENet) and is led by Dr. Patrick Cossette at the University of Montreal Hospital Research Centre* (CRCHUM), as well as co-leaders, Dr.

COPD patients starting to breathe easier

Wednesday, December 4, 2013

Two BC researchers have combined forces to develop  a blood test that will identify patients at high risk for Chronic Obstructive Pulmonary Disease (COPD) lung attacks. This much needed test will help medical professionals provide better treatment and ultimately lead to patients with fewer attacks, and reduced hospitalization and emergency visits.
 

CHU de Québec Collaborates with PerkinElmer on a study funded by Genome Canada, Génome Québec, CIHR and Genome Alberta using DNA sequencing alone or in a contingent model with first trimester serum markers as non-invasive option to determine risk of Down

Monday, November 4, 2013

A team of clinical researchers led by CHU de Québec has received CAN$10.5 million from Génome Québec, Genome Canada, CIHR, Genome Alberta and other partners to recruit 5,600 pregnant women in Canada to study the potential of using DNA sequencing alone or in a contingent model with first trimester serum markers as a non-invasive method for detecting birth defects.

Pages